• Je něco špatně v tomto záznamu ?

Applicability of EU(7)-PIM criteria in cross-national studies in European countries

D. Fialová, J. Brkić, B. Laffon, J. Reissigová, S. Grešáková, S. Dogan, P. Doro, L. Tasić, V. Marinković, V. Valdiglesias, S. Costa, J. Kostřiba,

. 2019 ; 10 (-) : 2042098619854014. [pub] 20190624

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035999

Background: The European Union (EU)(7)-PIM (potentially inappropriate medication) list presents the most comprehensive and up-to-date tool for evaluation of PIM prescribing in Europe; however, several country-specific studies have documented lower specificity of this list on pharmaceutical markets of some countries. The aim of our study was to describe approval rates and marketing of PIMs stated by EU(7)-PIM criteria in six EU countries [in comparison with the American Geriatric Society (AGS) Beers 2015 criteria]. Methods: Research teams of six EU countries (Czech Republic, Spain, Portugal, Serbia, Hungary and Turkey) participated in this study conducted by WG1b EU COST Action IS1402 group in the period October 2015-November 2018. Data on approval rates of PIMs and their availability on pharmaceutical markets have been obtained from databases of national drug-regulatory institutes and up-to-date drug compendia. The EU(7)-PIM list and AGS Beers 2015 Criteria (Section 1) were applied. Results: PIMs from EU(7)-PIM list were approved for clinical use more often than those from the AGS Beers 2015 criteria (Section 1). Approval rates for EU(7)-PIMs ranged from 42.8% in Serbia to 71.4% in Spain (for AGS criteria only from 36.4% to 65.1%, respectively). Higher percentages of approved PIMs were documented in Spain (71.4%), Portugal (67.1%) and Turkey (67.5%), lower in Hungary (55.5%), Czech Republic (50.2%) and Serbia (42.8%). The majority of approved PIMs were also currently marketed in all countries except in Turkey (19.8-21.7% not marketed PIMs) and less than 20% of PIMs were available as over-the-counter medications (except in Turkey, 46.4-48.1%). Conclusions: The EU(7)-PIM list was created for utilization in European studies; however, applicability of this list is still limited in some countries, particularly in Eastern and Central Europe. The EU project EUROAGEISM H2020 (2017-2021) that focuses on PIM prescribing and regulatory measures in Central and Eastern European countries must consider these limits.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035999
003      
CZ-PrNML
005      
20191105145335.0
007      
ta
008      
191007s2019 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1177/2042098619854014 $2 doi
035    __
$a (PubMed)31258888
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Fialová, Daniela $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, Hradec Králové 500 05, Czech Republic.
245    10
$a Applicability of EU(7)-PIM criteria in cross-national studies in European countries / $c D. Fialová, J. Brkić, B. Laffon, J. Reissigová, S. Grešáková, S. Dogan, P. Doro, L. Tasić, V. Marinković, V. Valdiglesias, S. Costa, J. Kostřiba,
520    9_
$a Background: The European Union (EU)(7)-PIM (potentially inappropriate medication) list presents the most comprehensive and up-to-date tool for evaluation of PIM prescribing in Europe; however, several country-specific studies have documented lower specificity of this list on pharmaceutical markets of some countries. The aim of our study was to describe approval rates and marketing of PIMs stated by EU(7)-PIM criteria in six EU countries [in comparison with the American Geriatric Society (AGS) Beers 2015 criteria]. Methods: Research teams of six EU countries (Czech Republic, Spain, Portugal, Serbia, Hungary and Turkey) participated in this study conducted by WG1b EU COST Action IS1402 group in the period October 2015-November 2018. Data on approval rates of PIMs and their availability on pharmaceutical markets have been obtained from databases of national drug-regulatory institutes and up-to-date drug compendia. The EU(7)-PIM list and AGS Beers 2015 Criteria (Section 1) were applied. Results: PIMs from EU(7)-PIM list were approved for clinical use more often than those from the AGS Beers 2015 criteria (Section 1). Approval rates for EU(7)-PIMs ranged from 42.8% in Serbia to 71.4% in Spain (for AGS criteria only from 36.4% to 65.1%, respectively). Higher percentages of approved PIMs were documented in Spain (71.4%), Portugal (67.1%) and Turkey (67.5%), lower in Hungary (55.5%), Czech Republic (50.2%) and Serbia (42.8%). The majority of approved PIMs were also currently marketed in all countries except in Turkey (19.8-21.7% not marketed PIMs) and less than 20% of PIMs were available as over-the-counter medications (except in Turkey, 46.4-48.1%). Conclusions: The EU(7)-PIM list was created for utilization in European studies; however, applicability of this list is still limited in some countries, particularly in Eastern and Central Europe. The EU project EUROAGEISM H2020 (2017-2021) that focuses on PIM prescribing and regulatory measures in Central and Eastern European countries must consider these limits.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Brkić, Jovana $u Department of Social and Clinical Pharmacy, Charles University, Czech Republic.
700    1_
$a Laffon, Blanca $u DICOMOSA Group, Department of Psychology, Universidade da Coruña, A Coruña, Spain.
700    1_
$a Reissigová, Jindra $u Department of Statistical Modeling, The Czech Academy of Sciences, Prague, Czech Republic.
700    1_
$a Grešáková, Silvia $u Department of Social and Clinical Pharmacy, Charles University, Czech Republic.
700    1_
$a Dogan, Soner $u Department of Medical Biology, Yeditepe University, Istanbul, Turkey.
700    1_
$a Doro, Peter $u Department of Clinical Pharmacy, University of Szeged, Szeged, Hungary.
700    1_
$a Tasić, Ljiljana $u Department of Social Pharmacy and Pharmaceutical Legislation, University of Belgrade, Belgrade, Serbia.
700    1_
$a Marinković, Valentina $u Department of Social Pharmacy and Pharmaceutical Legislation, University of Belgrade, Belgrade, Serbia.
700    1_
$a Valdiglesias, Vanessa $u DICOMOSA Group, Department of Psychology, Universidade da Coruña, A Coruña, Spain.
700    1_
$a Costa, Solange $u Department of Environmental Health, Portuguese National Institute of Health, Porto, Portugal.
700    1_
$a Kostřiba, Jan $u Department of Social and Clinical Pharmacy, Charles University, Czech Republic.
773    0_
$w MED00200679 $t Therapeutic advances in drug safety $x 2042-0986 $g Roč. 10, č. - (2019), s. 2042098619854014
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31258888 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191105145605 $b ABA008
999    __
$a ind $b bmc $g 1452659 $s 1074549
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 10 $c - $d 2042098619854014 $e 20190624 $i 2042-0986 $m Therapeutic advances in drug safety $n Ther Adv Drug Saf $x MED00200679
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Možnosti archivace